BioIntervene takes on adenosine in pain, raises $30M

BioIntervene founder pinpoints an adenosine receptor that may be able to safely treat neuropathic pain

With IP from St. Louis University and NIH, BioIntervene raised a $30 million series A round from MPM Capital to bring what could be a first-in-class pain therapy into the clinic.

The company plans to start a Phase I neuropathic pain trial next half of lead candidate BIO-205, an adenosine A3 receptor (ADORA3) agonist. The offering is expected to give BioIntervene enough runway to complete proof-of-concept studies.

MPM’s Ed Hurwitz, who serves as executive chairman of BioIntervene Inc., told BioCentury the firm was attracted by the novel biology the company had elucidated for the

Read the full 935 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE